CELGENE CORPORATION for CELGENE CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREG CHESMORE | — |
| STEPHEN RUBRIGHT | — |
| MATTHEW SCHUMAKER | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.